title: RAS and ROS in rhabdomyosarcoma.
abstract: The 5-year survival for localized rhabdomyosarcoma is over 70%, but only 30% for patients presenting with metastatic disease. In this issue of Cancer Cell, Chen and colleagues performed whole-genome and RNA sequencing on human rhabdomyosarcoma and identified RAS mutations and oxidative stress as potential therapeutic targets for high-risk embryonal rhabdomyosarcoma.
authors: Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA; Program in Molecular Cancer Biology, Duke University, Durham, NC 27710, USA.
authors: Minsi
authors: M
authors: Zhang
authors: Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA; Division of Hematology-Oncology, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA.
authors: Corinne M
authors: CM
authors: Linardic
authors: Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA; Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: david.kirsch@duke.edu.
authors: David G
authors: DG
authors: Kirsch
mesh_terms: D000818:Animals; D006801:Humans; D018384:Oxidative Stress; D018233:Rhabdomyosarcoma, Embryonal / Q000235:genetics*